PressApril 21, 2023 Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
PressApril 21, 2023 PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
PressApril 21, 2023 Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada
PressApril 21, 2023 Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
PressApril 21, 2023 Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
PressApril 21, 2023 Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
PressApril 17, 2023 FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
PressApril 17, 2023 Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023
PressApril 17, 2023 Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
PressApril 14, 2023 Sunstone Therapies Announces Publication of Positive Data on Use of Psilocybin Therapy for Patients with Cancer and Major Depression Disorder, in JAMA Oncology
PressApril 14, 2023 atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
PressApril 11, 2023 Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
PressApril 11, 2023 Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressApril 11, 2023 COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
PressApril 11, 2023 Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
